Dr Reddy's Labs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,350.50",
    "chg": 22.1,
    "chgp": "1.66%",
    "dir": 1,
    "prev_price": "1,328.40",
    "mcapval": "113,119.00 Cr",
    "mcap": "Large Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE089A01031",
    "curr_date": "Jun 25, 03:30 PM",
    "curr_time": "13:28 PM",
    "last_traded_at": "Jun 25, 03:30 PM IST",
    "bse_nse_vol": "18.25 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 25, 2026",
    "traded_date_str": "2026 06 25",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "P/E at 26.4 vs Industry's 34.7: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-shifts-4072696",
        "imagepath": "",
        "date": "2026-06-25 09:21:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The stock’s P/E ratio of 26.4 stands in contrast to the industry’s 34.66, indicating that <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> is trading at a 23.8% discount relative to its sector peers. This valuation gap suggests the market is pricing in either a more cautious outlook on growth or risk factors specific to the company. Such a discount is particularly notable given the sector’s generally positive earnings momentum, with 19 out of 35 stocks reporting positive results in the latest earnings season. <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Lt..."
      },
      {
        "title": "P/E at 25.87 vs Industry's 34.68: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-strengthens-position-amid-nifty-50-membership-4069921",
        "imagepath": "",
        "date": "2026-06-24 09:21:13",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E multiple of 25.87, which is approximately 25.4% lower than the Pharmaceuticals &amp; Biotechnology industry average of 34.68. This discount suggests that the market is pricing in either a more conservative growth outlook or risk factors relative to its peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> appears to be valued more cautiously. Investors might wonder <a href=\"https://www.marketsmojo...."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Technical Momentum Shifts Signal Bullish Outlook",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-technical-momentum-shifts-signal-bullish-outlook-4068079",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/DrReddysLaborat_technicaldot_4068079.png",
        "date": "2026-06-23 08:04:51",
        "description": "Dr Reddys Laboratories Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, suggesting a nuanced but positive outlook for the pharmaceutical giant amid a volatile market backdrop."
      },
      {
        "title": "P/E at 25.29 vs Industry's 34.06: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-shifts-4066828",
        "imagepath": "",
        "date": "2026-06-22 09:21:18",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E multiple of 25.29, which is approximately 25.7% below the Pharmaceuticals & Biotechnology industry average of 34.06. This discount suggests that the market is pricing in either a more cautious outlook on the company’s earnings growth or perceives risks not fully reflected in the broader sector valuation. The sector’s elevated P/E is often driven by growth expectations and innovation pipelines, but <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> appears to be valued more conservatively de..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-ltd-is-rated-hold-4063329",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/DrReddysLaborat_mojoScore_4063329.png",
        "date": "2026-06-19 10:10:04",
        "description": "Dr Reddys Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "P/E at 25.28 vs Industry's 33.88: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-challenges-amidst-nifty-50-membership-4062820",
        "imagepath": "",
        "date": "2026-06-19 09:21:19",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E ratio of 25.28 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands well below the industry average of 33.88, indicating a valuation discount of roughly 25%. This divergence suggests that the market is pricing in either a more cautious outlook on the company’s near-term earnings growth or perceives higher risks relative to its peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to growth prospects and innovation pipelines, so this discount merits close attention. <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Lab..."
      },
      {
        "title": "P/E at 25.24 vs Industry's 33.60: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-market-performance-4060681",
        "imagepath": "",
        "date": "2026-06-18 09:21:52",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands at 25.24, notably below the Pharmaceuticals &amp; Biotechnology industry average of 33.60. This represents a discount of approximately 24.9%, suggesting the market is pricing in either subdued growth expectations or risk factors relative to peers. Such a valuation gap is particularly striking given the company’s large-cap status and established market presence. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys L..."
      },
      {
        "title": "P/E at 25.42 vs Industry's 33.60: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-market-signals-4058486",
        "imagepath": "",
        "date": "2026-06-17 09:21:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E ratio of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> at 25.42 stands well below the sector average of 33.60, indicating a valuation discount of nearly 24%. This gap suggests the market is pricing in either a more cautious outlook on the company’s near-term earnings growth or reflecting concerns over competitive pressures within the Pharmaceuticals & Biotechnology sector. The sector’s elevated P/E is often driven by growth expectations and innovation pipelines, so the discount may imply a more conservative stance on <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk..."
      },
      {
        "title": "P/E at 25.46 vs Industry's 33.60: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-market-signals-4055537",
        "imagepath": "",
        "date": "2026-06-16 09:21:00",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of 25.46 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands well below the industry average of 33.60, signalling a valuation discount of nearly one-quarter relative to its peers. This gap suggests the market is pricing in either a more cautious outlook on earnings growth or risk factors specific to the company. In contrast, many large-cap pharmaceutical stocks continue to command premium multiples, reflecting expectations of robust innovation pipelines or steady cash flows. The discount may also reflect recent performance trends or sector rotation effects. <a href=\"https://www.marketsmojo.com/stocks..."
      }
    ],
    "total": 592,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "details": "Dr. Reddy's Laboratories Limited has submitted to the Exchange a copy of Disclosure of Related Party Transactions for the period ended September 30, 2019.",
      "source": "NSE",
      "caption": "Dr. Reddy's Laboratories Limited - Other General Purpose",
      "datetime": "28-Nov-2019"
    },
    {
      "details": "Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated November 22, 2019, titled \"Dr. Reddy's Laboratories announces launch of",
      "source": "NSE",
      "caption": "Dr. Reddy's Laboratories Limited - Press Release",
      "datetime": "22-Nov-2019"
    },
    {
      "details": "Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated November 14, 2019, titled \"Dr. Reddy s Laboratories enters Nutrition Segment with Celevida in India.\".",
      "source": "NSE",
      "caption": "Dr. Reddy's Laboratories Limited - Press Release",
      "datetime": "14-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "22 Jul 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 26",
          "dt": "2026-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

P/E at 26.4 vs Industry's 34.7: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-25 09:21:11

Valuation Picture: Discount Amidst Sector Premiums

The stock’s P/E ratio of 26.4 stands in contrast to the industry’s 34.66, indicating that Dr Reddys Laboratories Ltd is trading at a 23.8% discount relative to its sector peers. This valuation gap suggests the market is pricing in either a more cautious outlook on growth or risk factors specific to the company. Such a discount is particularly notable given the sector’s generally positive earnings momentum, with 19 out of 35 stocks reporting positive results in the latest earnings season. Dr Reddys Laboratories Lt...

Read full news article

P/E at 25.87 vs Industry's 34.68: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-24 09:21:13

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 25.87, which is approximately 25.4% lower than the Pharmaceuticals & Biotechnology industry average of 34.68. This discount suggests that the market is pricing in either a more conservative growth outlook or risk factors relative to its peers. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet Dr Reddys Laboratories Ltd appears to be valued more cautiously. Investors might wonder Read full news article

Dr Reddys Laboratories Ltd Technical Momentum Shifts Signal Bullish Outlook

2026-06-23 08:04:51

Dr Reddys Laboratories Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, suggesting a nuanced but positive outlook for the pharmaceutical giant amid a volatile market backdrop.

Read full news article

P/E at 25.29 vs Industry's 34.06: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-22 09:21:18

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 25.29, which is approximately 25.7% below the Pharmaceuticals & Biotechnology industry average of 34.06. This discount suggests that the market is pricing in either a more cautious outlook on the company’s earnings growth or perceives risks not fully reflected in the broader sector valuation. The sector’s elevated P/E is often driven by growth expectations and innovation pipelines, but Dr Reddys Laboratories Ltd appears to be valued more conservatively de...

Read full news article

Dr Reddys Laboratories Ltd is Rated Hold

2026-06-19 10:10:04

Dr Reddys Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

P/E at 25.28 vs Industry's 33.88: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-19 09:21:19

Valuation Picture: Discount Amidst Sector Premiums

The current P/E ratio of 25.28 for Dr Reddys Laboratories Ltd stands well below the industry average of 33.88, indicating a valuation discount of roughly 25%. This divergence suggests that the market is pricing in either a more cautious outlook on the company’s near-term earnings growth or perceives higher risks relative to its peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to growth prospects and innovation pipelines, so this discount merits close attention. Dr Reddys Lab...

Read full news article

P/E at 25.24 vs Industry's 33.60: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-18 09:21:52

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd stands at 25.24, notably below the Pharmaceuticals & Biotechnology industry average of 33.60. This represents a discount of approximately 24.9%, suggesting the market is pricing in either subdued growth expectations or risk factors relative to peers. Such a valuation gap is particularly striking given the company’s large-cap status and established market presence. The sector’s elevated P/E reflects optimism around innovation and pipeline potential, yet Dr Reddys L...

Read full news article

P/E at 25.42 vs Industry's 33.60: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-17 09:21:37

Valuation Picture: Discount Amidst Sector Premiums

The current P/E ratio of Dr Reddys Laboratories Ltd at 25.42 stands well below the sector average of 33.60, indicating a valuation discount of nearly 24%. This gap suggests the market is pricing in either a more cautious outlook on the company’s near-term earnings growth or reflecting concerns over competitive pressures within the Pharmaceuticals & Biotechnology sector. The sector’s elevated P/E is often driven by growth expectations and innovation pipelines, so the discount may imply a more conservative stance on Read full news article

P/E at 25.46 vs Industry's 33.60: What the Data Shows for Dr Reddys Laboratories Ltd

2026-06-16 09:21:00

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of 25.46 for Dr Reddys Laboratories Ltd stands well below the industry average of 33.60, signalling a valuation discount of nearly one-quarter relative to its peers. This gap suggests the market is pricing in either a more cautious outlook on earnings growth or risk factors specific to the company. In contrast, many large-cap pharmaceutical stocks continue to command premium multiples, reflecting expectations of robust innovation pipelines or steady cash flows. The discount may also reflect recent performance trends or sector rotation effects. Read full news article

View All News